Armata Pharmaceuticals, Inc. (ARMP)

CIK 0000921114 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q1-2026 8-K (2026-05-13) · 99.1
Latest FY-2025 8-K (2026-03-25) · 99.1
Q3-2025 8-K (2025-11-12) · 99.1
Q2-2025 8-K (2025-08-12) · 99.1
Q1-2025 8-K (2025-05-14) · 99.1
FY-2024 8-K (2025-03-21) · 99.1
Q3-2024 8-K (2024-11-13) · 99.1
Q2-2024 8-K (2024-08-13) · 99.1
Q1-2024 8-K (2024-05-07) · 99.1
FY-2023 8-K (2024-03-21) · 99.1
Q3-2023 8-K (2023-11-14) · 99.1
Q2-2023 8-K (2023-08-14) · 99.1  |  8-K (2023-06-27)  |  8-K (2023-05-12) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Condensed Consolidated Statements of Shareholders' Equity
—
Condensed Consolidated Statements of Stockholders' (deficit) Equity
—
Consolidated Statements of Shareholders' (deficit) Equity
Consolidated Statements of Stockholders' Deficit
Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (P)
Notes
Balance Sheet Details
Commitments and Contingencies
Convertible Debt
Convertible Loan
Cybersecurity Risk Management and Strategy Disclosure
—
Employee Retirement Plan
—
Equity Incentive Plans
Fair Value Measurements
Grants and Awards
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Liquidity
—
Liquidity and Going Concern
Long-term Debt
Net Income (loss) Per Share
—
Net Loss Per Share
Organization and Description of The Business
Pay Vs Performance Disclosure
Segment Reporting
Shareholders' Equity
—
Significant Accounting Policies
Stockholders' Deficit
Stockholders' Equity
—
Stockholders' Equity (deficit)
—
Subsequent Events
Term Debt